Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | CTSB | P07858 | 1/20 | 0.47 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.47 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | KYNU | Q16719 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | MMP8 | P22894 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL139859 | 1.00 | ALDH1A1 (0.53) | ALDH1A1THRBCYP2C9CYP2C19HSD17B10 | |
| Ammonia Solution, Strong SCHEMBL28148323 | 0.98 | ALDH1A1 (0.51) | ALDH1A1THRBCYP2C9CYP2C19HSD17B10 | |
| SCHEMBL6473025 | 0.87 | MMP8 (0.55) | ALDH1A1CTSBCTRB1TRPM8ALOX15 | |
| SCHEMBL28038097 | 0.87 | ALDH1A1 (0.53) | ALDH1A1KMT2AL3MBTL1MAPK1SLC6A2 | |
| SCHEMBL27696619 | 0.85 | ALDH1A1 (0.51) | ALDH1A1KMT2AL3MBTL1MAPK1SLC6A2 | |
| Hydrochloric Acid SCHEMBL4263030 | 0.84 | ALDH1A1 (0.50) | ALDH1A1KMT2AL3MBTL1MAPK1SLC6A2 | |
| Hydrochloric Acid SCHEMBL4263027 | 0.84 | ALDH1A1 (0.50) | ALDH1A1KMT2AL3MBTL1MAPK1SLC6A2 | |
| SCHEMBL27454064 | 0.83 | ALDH1A1 (0.49) | ALDH1A1KMT2AL3MBTL1MAPK1SLC6A2 | |
| SCHEMBL15177646 | 0.83 | HTT (0.49) | ALDH1A1KMT2AL3MBTL1MAPK1SLC6A2 | |
| Ammonia Solution, Strong SCHEMBL27854372 | 0.81 | ALDH1A1 (0.51) | ALDH1A1CYP2C9CYP2C19KMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240408080-A1 | PHARMACEUTICAL COMPOSITIONS OF CGRP INHIBITORS AND METHODS OF THEIR USE | PFIZER IRELAND PHARMACEUTICALS | 2024-12-12 | — | — | US | disclosed |
| EP-4284505-A1 | PHARMACEUTICAL COMPOSITIONS OF CGRP INHIBITORS AND METHODS OF THEIR USE | Pfizer Ireland Pharmaceuticals (IE) | 2023-12-06 | — | — | EP | disclosed |
| US-20220401439-A1 | INTRANASAL PHARMACEUTICAL COMPOSITIONS OF CGRP INHIBITORS | PFIZER IRELAND PHARMACEUTICALS (IE) | 2022-12-22 | — | — | US | disclosed |
| EP-4076395-A1 | INTRANASAL PHARMACEUTICAL COMPOSITIONS OF CGRP INHIBITORS | Biohaven Pharmaceutical Holding Company Ltd. (US) | 2022-10-26 | — | — | EP | disclosed |
| CN-114980862-A | Intranasal pharmaceutical compositions of CGRP inhibitors | 拜尔哈文制药股份有限公司 | 2022-08-30 | — | — | CN | disclosed |
| WO-2022165291-A1 | PHARMACEUTICAL COMPOSITIONS OF CGRP INHIBITORS AND METHODS OF THEIR USE | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. (US) | 2022-08-04 | — | — | WO | disclosed |
| WO-2021127070-A1 | INTRANASAL PHARMACEUTICAL COMPOSITIONS OF CGRP INHIBITORS | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. (US) | 2021-06-24 | — | — | WO | disclosed |
| EP-2552906-B1 | CGRP RECEPTOR ANTAGONIST | BRISTOL MYERS SQUIBB CO (US) | 2016-01-06 | — | — | EP | disclosed |
| CN-102834388-B | Cgrp receptor antagonist | BRISTOL MYERS SQUIBB CO | 2014-07-16 | — | — | CN | disclosed |
| US-8481546-B2 | CGRP receptor antagonist | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-07-09 | — | — | US | disclosed |
| EP-2552906-A1 | CGRP RECEPTOR ANTAGONIST | Bristol-Myers Squibb Company (US) | 2013-02-06 | — | — | EP | disclosed |
| CN-102834388-A | Cgrp receptor antagonist | BRISTOL MYERS SQUIBB CO | 2012-12-19 | — | — | CN | disclosed |
| US-20120059017-A1 | CGRP Receptor Antagonist | BRISTOL-MYERS SQUIBB COMPANY | 2012-03-08 | — | — | US | disclosed |
| WO-2011123232-A1 | CGRP RECEPTOR ANTAGONIST | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-10-06 | — | — | WO | disclosed |
| US-7449586-B2 | Processes for the preparation of CGRP-receptor antagonists and intermediates thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-11-11 | — | — | US | disclosed |
| US-20060122250-A1 | Novel processes for the preparation of CGRP-receptor antagonists and intermediates thereof | BRISTOL-MYERS SQUIBB COMPANY | 2006-06-08 | — | — | US | disclosed |
| WO-2006060678-A2 | NOVEL PROCESSES FOR THE PREPARATION OF CGRP-RECEPTOR ANTAGONISTS AND INTERMEDIATES THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220401439-A1 | INTRANASAL PHARMACEUTICAL COMPOSITIONS OF CGRP INHIBITORS | CALCA, CALCB, CALCRL | ALDH1A1 2986/4885THRB 2849/4885CYP2C9 1900/4885 |
| US-20240408080-A1 | PHARMACEUTICAL COMPOSITIONS OF CGRP INHIBITORS AND METHODS OF THEIR USE | CALCA, CALCB, CALCRL | ALDH1A1 2302/4885THRB 2496/4885CYP2C9 1601/4885 |
| US-20060122250-A1 | Novel processes for the preparation of CGRP-receptor antagonists and intermediates thereof | CALCR, CALCRL, CALCB | ALDH1A1 2702/4885THRB 290/4885CYP2C9 1820/4885 |
| US-20120059017-A1 | CGRP Receptor Antagonist | CALCRL, PTGIR, CALCR | ALDH1A1 1718/4885THRB 1001/4885CYP2C9 1906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.